Clinical Trial Update: A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of abemaciclib in women with HR+, HER2+ locally advanced or metastatic breast cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-05-26